checkAd

     139  0 Kommentare electroCore, Inc. Announces Regulatory Approval in Canada - Seite 2

    For more information, visit www.rskmedical.com  

    About Migraine Canada
    Migraine Canada is an alliance of patients and health care providers working together to improve the lives of people living with migraine and other headache disorders in Canada, through awareness, support, education, advocacy and research

    For more information, visit www.migrainecanada.org

    About gammaCoreTM

    gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. 

    gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
    gammaCore contraindications include but are not limited to:

    • Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
    • Patients with a metallic device, such as a stent, bone plate or bone screw, implanted at or near the neck
    • Patients who are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

    Safety and efficacy of gammaCore have not been evaluated in the following patients:

    • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
    • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
    • Pediatric patients (less than 12 years of age)
    • Pregnant women
    • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

    Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

    Seite 2 von 4



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    electroCore, Inc. Announces Regulatory Approval in Canada - Seite 2 ROCKAWAY, NJ, April 05, 2021 (GLOBE NEWSWIRE) - electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Health Canada has granted regulatory approval for the promotion and sale of the gammaCore …